4D Molecular Therapeutics, Inc. — Revenue by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/0daf19c0-d5ee-4b6c-b853-3abd850c0607/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $85.2M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-114075 |
| FY 2024 | $37.0k | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-030056 |
| FY 2023 | $20.7M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-023183 |
| FY 2022 | $3.1M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-008142 |
| FY 2021 | $18.0M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-004794 |
| FY 2020 | $13.4M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-015502 |
| FY 2019 | $7.0M | 2019-01-01 – 2019-12-31 | evidence 0001564590-21-015502 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
4D Molecular Therapeutics, Inc. — all facts · Net Income · Operating Income